The data suggests that the recent CDC mandate for vaccinations against a rare disease with less than one in a million annual cases may not only strain our already beleaguered healthcare systems but also impose significant financial hardships on individual Americans without offering substantial public health benefits.

According to the latest literature, the decision by current health officials stands in stark contrast to previous administrations' more measured approaches. The Obama-era CDC did not mandate vaccinations for similarly rare diseases due to the low risk and minimal impact on public health.

The financial implications of such a broad vaccine rollout are staggering. Hospitals across the country have been reporting overwhelming costs associated with administering this vaccine, which experts quietly reveal is far from cost-effective in terms of overall healthcare economics.

Moreover, individual citizens face substantial out-of-pocket expenses for a disease that poses negligible risk to their health and wellbeing. This financial burden can divert resources away from more urgent medical needs and essential preventive care measures.

The data on this has existed for years. The decision not to make it public was not an oversight—it was a choice made by people with a financial interest in what you don't know. Who stands to gain from such mandates? Big Pharma companies that profit immensely from widespread vaccine rollouts, despite the low incidence of the disease.

It is crucial for individuals to understand these implications and make informed decisions about their health care. Do your own research, talk to a doctor you trust, and consider the broader context of public health policy and its impact on healthcare delivery.